ANTIPYRINE CLEARANCE PER UNIT VOLUME LIVER - ASSESSMENT OF HEPATIC-FUNCTION IN CHRONIC LIVER-DISEASE

被引:49
作者
HOMEIDA, M
ROBERTS, CJC
HALLIWELL, M
READ, AE
BRANCH, RA
机构
[1] BRISTOL ROYAL INFIRM, DEPT PHYS, BRISTOL BS2 8HW, AVON, ENGLAND
[2] VANDERBILT UNIV, SCH MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37240 USA
关键词
D O I
10.1136/gut.20.7.596
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver size has been estimated clinically and by a non-invasive ultrasound technique in 16 normal subjects, 16 patients with cirrhosis, 10 patients with chronic biliary obstruction, and three patients with primary hepatoma. Antipyrine disposition was also measured in each subject. Hepatomegaly was not clinically detectable until there was approximately a 20% increase in liver size. Additional increases in size correlated significantly with clinical estimates of hepatomegaly. Antipyrine clearance has a three-fold range in normal subjects. Its mean value was significantly reduced in each subgroup of patients with liver disease. However, 48% of patients with liver disease had values within the normal range. In normal subjects there was a significant correlation between antipyrine clearance and liver volume. Thus, intersubject variation in clearance normalised for liver volume was less than clearance alone. Antipyrine clearance normalised for liver volume in patients with liver disease was significantly lower than in normal subjects and there was no overlap with normal subjects. In conclusion, assessment of drug metabolising efficiency per unit volume of liver increased the discrimination of differentiating subjects with normal from abnormal livers.
引用
收藏
页码:596 / 601
页数:6
相关论文
共 24 条
[1]  
ANDREASE.B, 1974, EUR J CLIN INVEST, V4, P129
[2]  
ANDREASEN PB, 1974, CLIN PHARMACOL THER, V16, P1059
[3]   PHENAZONE METABOLISM IN PATIENTS WITH LIVER-DISEASE [J].
ANDREASEN, PB ;
GREISEN, G .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1976, 6 (01) :21-26
[4]   STUDY OF FACTORS INFLUENCING DRUG DISPOSITION IN CHRONIC LIVER-DISEASE, USING MODEL DRUG (+)-PROPRANOLOL [J].
BRANCH, RA ;
JAMES, J ;
READ, AE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (02) :243-249
[5]  
BRANCH RA, 1976, CLIN PHARMACOL THER, V20, P81
[6]   DETERMINANTS OF SERUM ANTIPYRINE HALF-LIVES IN PATIENTS WITH LIVER-DISEASE [J].
BRANCH, RA ;
HERBERT, CM ;
READ, AE .
GUT, 1973, 14 (07) :569-573
[7]  
BRODIE BB, 1949, J BIOL CHEM, V179, P25
[8]  
BRODIE BB, 1950, J PHARMACOL EXP THER, V98, P97
[9]  
FARRELL GC, 1976, GASTROENTEROLOGY, V71, P905
[10]   QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION BY BREATH ANALYSIS AFTER ORAL-ADMINISTRATION OF [AMINOPYRINE-C-14 [J].
HEPNER, GW ;
VESELL, ES .
ANNALS OF INTERNAL MEDICINE, 1975, 83 (05) :632-638